Adalimumab for treatment of very early onset inflammatory bowel disease

Chin Med J (Engl). 2019 Dec 5;132(23):2889-2890. doi: 10.1097/CM9.0000000000000528.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / therapeutic use*
  • Age of Onset
  • Blood Sedimentation / drug effects
  • C-Reactive Protein / metabolism
  • Humans
  • Infant, Newborn
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / metabolism
  • Inflammatory Bowel Diseases / physiopathology
  • Male
  • Treatment Outcome

Substances

  • C-Reactive Protein
  • Adalimumab